Algorae Pharmaceuticals Limited (LVCLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Algorae Pharmaceuticals Limited (LVCLF) trades at $0.01 with AI Score 46/100 (Grade C). Algorae Pharmaceuticals Limited (LVCLF) is a biotechnology company focused on developing innovative therapies for neurological and cardiovascular diseases. Market cap: $16.36M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for LVCLF: LVCLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LVCLF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LVCLF: the 1 perspectives are evenly split.
How is this calculated? →Algorae Pharmaceuticals Limited (LVCLF) Healthcare & Pipeline Overview
Algorae Pharmaceuticals Limited specializes in developing advanced therapeutics for serious health conditions, including dementia and Parkinson's disease, with a focus on innovative living cell technologies and artificial intelligence-driven drug development.
What Is the Investment Thesis for LVCLF?
Algorae Pharmaceuticals Limited presents a compelling case for growth within the biotechnology sector, driven by its innovative product pipeline and strategic partnerships. The company’s market capitalization stands at approximately $14.39 million, reflecting its potential for expansion as it advances its clinical candidates. Key value drivers include the ongoing development of AI-116, NTCELL, and AI-168, which target significant health issues like dementia and Parkinson's disease, expected to see increased demand due to aging populations. The partnership with the University of New South Wales for AlgaraeOS enhances the company's capability to innovate in drug development, potentially positioning it ahead of competitors. However, risks include the inherent volatility of OTC trading, limited liquidity, and the challenges associated with regulatory approvals for its drug candidates. Investors should monitor clinical trial results and regulatory milestones closely, as these will be crucial in determining the company's future trajectory.
Based on FMP financials and quantitative analysis
LVCLF Key Highlights
- Market capitalization of approximately $14.39 million, indicating a small-cap status with potential for growth.
- Focus on innovative therapies targeting high-prevalence conditions such as dementia and Parkinson's disease.
- Strong collaboration with the University of New South Wales to develop AI-driven drug prediction technology.
- No dividend yield, reflecting a reinvestment strategy typical for early-stage biotechnology firms.
- Beta of -0.08, suggesting lower volatility compared to the broader market.
Who Are LVCLF's Competitors?
LVCLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals Inc. | $15.62 | +0.06% | $2.01B | 57 |
| NVAX Novavax, Inc. | $9.35 | -4.00% | $1.54B | — |
| CRIS Curis, Inc. | $5.94 | -14.31% | 12M | — |
| PFE Pfizer Inc. | $23.72 | -2.47% | 136B | 64 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LVCLF's Key Strengths?
- Innovative product pipeline targeting significant health issues.
- Strong partnerships enhancing research capabilities.
- Experienced management team with industry expertise.
- Proprietary technologies that differentiate offerings.
What Are LVCLF's Weaknesses?
- Limited market presence compared to larger competitors.
- Dependence on successful clinical trial outcomes.
- No current revenue streams due to the early-stage nature of products.
- Higher volatility associated with OTC trading.
What Are the Key Risks for LVCLF?
- Negative return on equity (-49.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What Are the Growth Opportunities for LVCLF?
- Growth opportunity 1: The global dementia treatment market is projected to reach $20 billion by 2026, driven by an aging population and increasing prevalence of Alzheimer's disease. Algorae's AI-116, targeting these conditions, positions the company to capitalize on this expanding market with its innovative combination therapy approach.
- Growth opportunity 2: The Parkinson's disease treatment market is expected to grow to $6 billion by 2025, fueled by advancements in drug development and increasing patient awareness. Algorae's NTCELL offers a novel therapeutic option, potentially capturing market share in this growing segment.
- Growth opportunity 3: The cardiovascular drug market is anticipated to reach $1 trillion by 2027, with hypertension treatments being a significant contributor. Algorae's AI-168, which combines cannabinoids with existing pharmaceuticals, could address this need and benefit from the market's expansion.
- Growth opportunity 4: The collaboration with the University of New South Wales on AlgaraeOS could enhance Algorae's research capabilities, allowing for the identification of new drug targets and accelerating the drug development process. This AI platform could streamline operations and improve the success rate of clinical trials.
- Growth opportunity 5: The increasing focus on personalized medicine and targeted therapies in the healthcare sector presents a significant opportunity for Algorae. By continuing to innovate and adapt its product offerings, Algorae can align with market trends and meet the evolving needs of patients and healthcare providers.
What Opportunities Does LVCLF Have?
- Growing demand for novel therapies in neurology and cardiology.
- Potential for expansion into international markets.
- Increasing focus on AI in drug development.
- Collaborative opportunities with larger pharmaceutical companies.
What Threats Does LVCLF Face?
- Intense competition from established biotech firms.
- Regulatory challenges in drug approval processes.
- Market volatility affecting investor sentiment.
- Potential for patent expirations impacting product exclusivity.
What Are LVCLF's Competitive Advantages?
- Strong focus on innovative therapies that address high-prevalence diseases.
- Proprietary living cell technologies that differentiate product offerings.
- Strategic partnerships with academic institutions for advanced research.
- A unique AI-driven platform for predicting drug targets, enhancing R&D efficiency.
- A dedicated team with expertise in biotechnology and pharmaceutical development.
What Does LVCLF Do?
Founded in 1987, Algorae Pharmaceuticals Limited is a Melbourne-based pharmaceutical development company that has evolved significantly over the years. Originally operating under the name Living Cell Technologies Limited, the company rebranded to Algorae Pharmaceuticals Limited in September 2023 to better reflect its focus on innovative therapeutic solutions. Algorae conducts its research and development primarily in New Zealand, where it leverages advanced living cell technologies to create groundbreaking treatments. The company’s product pipeline includes several promising candidates: AI-116, a novel combination therapy that pairs cannabidiol with an existing pharmaceutical ingredient to target dementia and Alzheimer's disease; NTCELL, an alginate-coated capsule designed to address Parkinson's disease; and AI-168, another combination drug that merges a cannabinoid with an off-patent pharmaceutical ingredient aimed at treating cardiovascular conditions such as hypertension. In collaboration with the University of New South Wales, Algorae is also developing AlgaraeOS, a cutting-edge artificial intelligence platform intended to predict biopharmaceutical drug targets. This innovative approach allows for the exploration of both fixed-dose combinations and repurposed drugs without being limited by specific medical indications. With a dedicated workforce of 48 employees, Algorae Pharmaceuticals is committed to advancing healthcare through its unique and targeted drug development initiatives.
What Products and Services Does LVCLF Offer?
- Develop innovative therapies targeting neurological and cardiovascular diseases.
- Conduct research and development primarily in New Zealand.
- Utilize living cell technologies to create advanced pharmaceutical solutions.
- Collaborate with academic institutions for cutting-edge research.
- Focus on combination therapies to enhance treatment efficacy.
- Leverage artificial intelligence for drug target prediction.
How Does LVCLF Make Money?
- Generate revenue through the development and commercialization of pharmaceutical products.
- Engage in partnerships and collaborations to enhance research capabilities.
- Focus on clinical trials to advance product candidates toward regulatory approval.
- Explore licensing agreements for successful drug candidates.
- Invest in R&D to expand the product pipeline and address unmet medical needs.
What Industry Does LVCLF Operate In?
The biotechnology industry is experiencing significant growth, driven by advancements in technology and increasing demand for innovative therapies. The global biotechnology market is expected to reach $2.4 trillion by 2028, with a CAGR of over 7%. Algorae Pharmaceuticals Limited operates within this dynamic landscape, focusing on unmet medical needs in neurology and cardiology. The competitive landscape includes established players and emerging biotech firms, with a growing emphasis on personalized medicine and AI-driven drug development, positioning Algorae favorably as it leverages its unique technologies.
Who Are LVCLF's Key Customers?
- Healthcare providers seeking innovative treatment options.
- Patients suffering from neurological and cardiovascular diseases.
- Pharmaceutical partners interested in collaboration and licensing.
- Research institutions engaged in biopharmaceutical development.
- Investors looking for opportunities in the biotechnology sector.
How Algorae Pharmaceuticals Limited Is Valued
Algorae Pharmaceuticals Limited carries a market capitalization of $16.36M, placing it in the micro-cap category. Relative to its peer group, LVCLF's quantitative score of 46/100 is below the peer average of 70/100.
Company Profile
Algorae Pharmaceuticals Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO David Richard Hainsworth. LVCLF has traded publicly since 2010.
ROE -49%Key Financial Metrics
Return on equity for Algorae Pharmaceuticals Limited stands at -49.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -50.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Algorae Pharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 65.66 places it in the safe zone, indicating low near-term bankruptcy risk.
LVCLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Algorae's recent insider buying suggests strong confidence from those closest to the company, signaling potential future growth. This is similar to when insiders loaded up on Tesla shares before its 2020 surge.
- Community sentiment shows increased optimism around Algorae's pipeline, with many believing their novel approach could disrupt the market. Think of the early buzz around CRISPR gene editing.
- The market perception of Algorae is shifting towards recognizing the value of their unique drug development strategy. This is akin to how the market eventually understood the potential of cloud computing.
- Positive community buzz highlights potential partnerships and collaborations, which could significantly expand Algorae's reach and accelerate development. This reminds me of the partnerships that fueled Gilead's growth.
Bear Case
- Recent community discussions reveal concerns about the timeline for Algorae's drug approvals, creating uncertainty about near-term revenue. Similar delays have hurt other biotechs like MannKind.
- Some community members express skepticism about Algorae's ability to compete with larger, established pharmaceutical companies. This is a common concern for smaller players in competitive industries.
- Negative sentiment has emerged regarding potential regulatory hurdles and the complexity of bringing novel drugs to market. Regulatory challenges crippled many aspiring biotechs during the 2008 financial crisis.
- There's a growing worry within the community about potential dilution through future fundraising efforts, which could negatively impact shareholder value. This concern often surfaces with smaller, growth-stage companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LVCLF Latest News
No recent news available for LVCLF.
LVCLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LVCLF.
Price Targets
Wall Street price target analysis for LVCLF.
LVCLF MoonshotScore
What does this score mean?
The MoonshotScore rates LVCLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
LVCLF OTC Market Information
LVCLF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
What Investors Ask About Algorae Pharmaceuticals Limited (LVCLF) — Healthcare
What are the key factors to evaluate for LVCLF?
Algorae Pharmaceuticals Limited (LVCLF) holds an AI score of 46/100 (low). Not financial advice.
How frequently does LVCLF data refresh on this page?
LVCLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LVCLF's recent stock price performance?
Algorae Pharmaceuticals Limited (LVCLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting significant health issues. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LVCLF overvalued or undervalued right now?
Valuing Algorae Pharmaceuticals Limited (LVCLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LVCLF?
Before investing in Algorae Pharmaceuticals Limited (LVCLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LVCLF to a portfolio?
Key strength of Algorae Pharmaceuticals Limited (LVCLF): Innovative product pipeline targeting significant health issues. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of LVCLF?
Yes, most major brokerages offer fractional shares of Algorae Pharmaceuticals Limited (LVCLF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track LVCLF's earnings and financial reports?
Algorae Pharmaceuticals Limited (LVCLF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for LVCLF earnings announcements is recommended.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.